Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC-02-3
- Development stage
- Preclinical
- Lead developer
- CompleCure
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**CC-02-3** is a preclinical HER2-targeted antibody-drug conjugate developed by CompleCure for HER2-positive advanced or recurrent ovarian cancer. CompleCure describes the CC-02 series as using a doxorubicin cytotoxic payload and identifies CC-02-3 as incorporating a combination-payload approach that includes an ATR inhibitor. The program is intended to selectively deliver antitumor activity to HER2-expressing tumor cells while combining DNA-damaging cytotoxic activity with inhibition of the ATR-mediated DNA-damage-response pathway.
02
Targets
ATR (ATR serine/threonine kinase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNA
Beyond the preview
Go deeper on CC-02-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC-02-3.